Gastrointestinal Drugs Market Size, Growth, Analysis 2021, 2027

The gastrointestinal drugs market was valued at US$ 49,043.38 million in 2019 and is projected to reach US$ 71,300.28 million by 2027; it is expected to grow at a CAGR of 4.9% from 2020 to 2027.

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms, such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits globally. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rise in investments in the development of biologics and emergence of biosimilars are expected to drive the growth of the market in the forecast period.

The scope of the gastrointestinal drugs market includes drug class, route of administration, application, distribution channel, and region. The market for gastrointestinal drugs is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the gastrointestinal drugs market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.

Strategic Insights

Lucrative Regions for Gastrointestinal Drugs Market

Get more information on this report : Request Free Sample PDF

Market Insights

Rise in Prevalence of Gastrointestinal (GI) Diseases

Gastrointestinal diseases are the conditions that occur in the gastrointestinal tract. Common digestive problems include heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), constipation, and diarrhea. GI diseases account for substantial health care utilization and spending. According to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), around 10 million people are living with IBD worldwide. Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats.

Western countries, such as the US, Canada, and the UK, are witnessing a high GI incidence rate due to increasing obesity in the adult population and less consumption of dietary fibers. As per the Centers for Disease Control and Prevention, in 2018, the number of visits to physician offices with the digestive system's diseases as the primary diagnosis was 22.4 million in the US. The incidence and prevalence of GI disorders are higher in the adult and elderly population. As the population ages, the disease burden is expected to increase. The GI disorders, such as inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis, are common, chronic inflammatory conditions that affect a vast population worldwide. This is due to a sedentary lifestyle, changing dietary habits, stress, and other factors. The incidence and prevalence of IBS have increased in the last few decades worldwide. As per the International Foundation for Gastrointestinal Disorders, Inc., IBS is the most common functional GI disorder with a prevalence rate of 10–15% globally. Also, it is one of the most common conditions for a visit to a doctor. There are around 2.4–3.5 million physician visits for IBS annually in the US. The cost of direct medical expenses and indirect costs associated with loss of productivity and work absenteeism due to IBS is estimated to be around US$ 21 billion annually.

Moreover, in the last few years, the cases of IBD have increased worldwide. IBD is a chronic inflammation of the digestive tract and is of two types: Ulcerative colitis and Crohn's disease. As per the Crohn’s & Colitis Foundation of America, IBD affects approximately 1.6 million Americans. Around 70,000 new cases of IBD are diagnosed every year in the US. Apart from the US, Europe is also witnessing increasing burden of chronic digestive diseases due to the aging population and lifestyle factors such as rising obesity and heavy alcohol consumption. For instance, as per the EFCCA, around 3.4 million people in Europe are living with IBD. Thus, the factors mentioned above are driving the adoption of GI drugs during the forecast period.

Drug Class-BasedInsights                                    

Based on drug class, the gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others. In 2019, the acid neutralizerssegment accounted for the highest share of the market. Growth of this segment is attributed to increasing incidence of GERD and rising patient pool across the globe. However, the biologicssegment likely to register the highest CAGR in the global gastrointestinal drugsmarket during the forecast period.

Global Gastrointestinal Drugs Market, by Drug Class– 2019& 2027

Get more information on this report : Request Free Sample PDF

Route of Administration-Based Insights

In terms ofroute of administration, the gastrointestinal drugsmarket is segmented into oral and parenteral. The oral segment held the largest share of the market in 2019, whereas the same segment is estimated to register the highest CAGR of 5.2% in the market during the forecast period.

Application-BasedInsights

Based on application, the gastrointestinal drugsmarket is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. The inflammatory ulcerative colitissegment held the largest share of the market in 2019, whereas the irritable bowel syndromesegment is projected to register the highest CAGR of 5.8% in the market during the forecast period.

Distribution Channel-Based Insights

In terms ofdistribution channel, the gastrointestinal drugsmarket is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmaciessegment held the largest share of the market in 2019, and same segment is expected to register the highest CAGR of 5.4% in the market during the forecast period.                                                                                       

Product launches and expansion strategy are commonly adopted by companies to expand their footprint worldwide and meet the growing demand. These strategiesare commonly adopted by the market players in order to expand its product portfolio.

The market players operating in the gastrointestinal drugs market adopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.

By Drug Class

• Acid Neutralizers
• Antidiarrheal and Laxatives
• Anti-Inflammatory Drugs
• Antiemetic and Antinauseants
• Biologics
• Others

By Route of Administration                          

• Oral
• Parenteral

By Application

• Inflammatory Ulcerative Colitis
• Crohn's Disease
• Irritable Bowel Syndrome
• Gastroenteritis
• Celiac Disease
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • Italy
  • UK
  • Spain

• Asia Pacific(APAC)

  • China
  • India
  • South Korea
  • Japan
  • Australia

• Middle East & Africa (MEA)

  • South Africa
  • Saudi Arabia
  • UAE

• South America (SAM)

  • Brazil
  • Argentina

Company Profiles

• Sanofi
• GlaxoSmithKline plc
• Johnson and Johnson Services, Inc.
• Bausch Health
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Bayer AG
• Celltrion Healthcare Co., Ltd.
• LEXICON PHARMACEUTICALS, INC